IntelGenx Corp. Announces Commencement of Pivotal Clinical Trial for Anti-Migraine VersaFilm
4/24/2012 9:57:31 AM
SAINT LAURENT, Quebec, April 24, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced the commencement of a pivotal bioequivalence clinical trial with its anti-migraine VersaFilm product, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. The screening and recruitment of all subjects for the trial has been completed, and first dosing commenced on April 23, 2012.
comments powered by